Companies Dominating the Bispecific Antibody Market
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Innovent Biologics, Ltd.
- Affimed GmbH
- Pieris Pharmaceuticals, Inc.
- Mereo BioPharma Group plc
- TG Therapeutics, Inc.
- MacroGenics, Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- AbbVie, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- GlaxoSmithKline plc in a joint venture with Vir Biotechnology, Inc. announced the collaboration with the government of the United States. With this agreement, the companies will fulfill the need for 600,000 extra doses of Sotrovimab, it is a monoclonal antibody for the early treatment of COVID-19.
- AbbVie Inc. announced the approval of the U.S. FDA for the world’s first and only T-cell-engaging bispecific antibody, EPKINLY. It is targeted for the treatment of persistent or refractory diffuse large B-cell lymphoma (DLBCL) in adults.
